标题
Mitigating the toxic effects of anticancer immunotherapy
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 11, Issue 2, Pages 91-99
出版商
Springer Nature
发表日期
2014-01-21
DOI
10.1038/nrclinonc.2013.245
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ipilimumab-Associated Colitis: CT Findings
- (2013) Kyung Won Kim et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- (2013) G. P. Linette et al. BLOOD
- Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
- (2013) C. Robert et al. CLINICAL CANCER RESEARCH
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
- (2013) Michael Kalos et al. IMMUNITY
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Cancer Advances 2012 and Neoadjuvant Chemoradiotherapy in Operable Gastroesophageal Cancers
- (2013) Peter A. Beatty et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
- (2013) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Checkpoint Blockade — Taking Melanoma Immunotherapy to the Next Level
- (2013) James L. Riley NEW ENGLAND JOURNAL OF MEDICINE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
- (2013) Jessica Ann Chacon et al. PLoS One
- T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy
- (2013) S. Zhong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Strength of PD-1 signaling differentially affects T-cell effector functions
- (2013) F. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells
- (2013) B. J. Cameron et al. Science Translational Medicine
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
- (2013) Robert H. Vonderheide et al. OncoImmunology
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
- (2012) B. G. Till et al. BLOOD
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
- (2011) S. Wilgenhof et al. ANNALS OF ONCOLOGY
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice
- (2011) Ronald P. Gladue et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Thyroid Dysfunction from Antineoplastic Agents
- (2011) O.-P. R. Hamnvik et al. JNCI-Journal of the National Cancer Institute
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
- (2010) S. Mocellin et al. JNCI-Journal of the National Cancer Institute
- Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
- (2010) Renier Brentjens et al. MOLECULAR THERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
- (2010) Anna Maria Di Giacomo et al. SEMINARS IN ONCOLOGY
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- (2010) Paolo A. Ascierto et al. SEMINARS IN ONCOLOGY
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues
- (2008) Giao Q. Phan et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
- (2008) J. D. Wolchok et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now